Related Experiment Video

Updated: Jul 11, 2025

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.8K

A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics

Hyeong-Min Lee1, William C Wright1, Min Pan1

  • 1Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.

Nature Communications
|November 13, 2023
PubMed

Insights

Discovering effective cancer drug combinations is challenging. This study uses CRISPR screens to map genes that sensitize cancer cells to chemotherapy, identifying improved combination therapies for neuroblastoma and other cancers.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Combination chemotherapy is vital for cancer treatment but discovering effective drug pairings is difficult.
  • Neuroblastoma, a common pediatric cancer, has poor outcomes for high-risk patients, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To develop a method for discovering synergistic drug combinations using large-scale CRISPR knockout screens.
  • To identify genetic vulnerabilities that sensitize cancer cells, particularly neuroblastoma, to existing chemotherapeutics.

Main Methods:

  • Conducted large-scale targeted CRISPR knockout screens across 18 cell lines (10 neuroblastoma, 8 others) treated with 8 common chemotherapy drugs.
  • Generated 94,320 unique combination-cell line perturbations to create a genetic map of drug sensitization.
  • Performed dense drug-drug rescreening to validate CRISPR-nominated combinations.

Main Results:

  • CRISPR-identified drug combinations demonstrated greater synergy compared to standard-of-care combinations.
  • Inhibition of PRKDC (non-homologous end-joining pathway) sensitized high-risk neuroblastoma cells to doxorubicin.
  • Validated PRKDC inhibition and doxorubicin synergy in vitro and in vivo using patient-derived xenograft (PDX) models.

Conclusions:

  • Targeted CRISPR screens provide a feasible and powerful approach to discover novel, synergistic cancer drug combinations.
  • This methodology offers a valuable resource for improving existing chemotherapies and developing new treatment strategies across various cancers.
  • The findings highlight PRKDC as a potential therapeutic target to enhance doxorubicin efficacy in neuroblastoma.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K
QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii11:37

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

Published on: June 22, 2017

16.3K

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.0K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.0K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
17
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.6K